NEW YORK (Reuters) - A U.S. judge ruled in favor of shareholders suing Bristol-Myers Squibb BMY about its disclosures while settling patent litigation with Canadian generic drug maker Apotex Inc over the blood-thinner Plavix. Manhattan federal court Judge Paul Crotty wrote that the...
The widely used anti-clotting drug Plavix appears to have a stronger effect in people who smoke, a study indicates. Plavix clopidogrel is often given to heart attack patients after the attack. It inhibits formation of clots by blood cells called platelets. The study of 259 people given Plavix because of...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/490602/cardiology_acute) has announced the addition of the "Cardiology - Acute Coronary Syndrome, Anticoagulants" report to their offering. This report provides in-depth analysis of the market and pipeline from the perspective of global thought leaders. This report is...
REYKJAVIK, Iceland, June 30 /PRNewswire-FirstCall/ -- deCODE genetics today announced positive topline results from its latest clinical pharmacology study of DG041, the company's first-in-class antagonist of the EP3 receptor for prostaglandin E2, developed as a next-generation oral anti-platelet therapy for preventing arterial thrombosis without increasing...
Reportlinker.com announces that a new market research report related to the Cardiovascular diseases industry is available in its catalogue. Blood Disorders Market Analysis and Forecasts Report to 2013 http://www.reportlinker.com/p090280/Blood-Disorders-Market-Analysis-and-Forecasts-Report-to-2013.html In 2007, blood diseases cost the US's economy $114bn. In 2004, a reported 232,000 deaths...
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/b7b104/all_change_in_the) has announced the addition of the "All Change in the US Pharma Market?" report to their offering. This extensive report provides a unique analysis of the likely impact of generic competition in the US pharma market. ...
Companies confirm the start of TRILOGY ACS clinical trial to study Prasugrel against Clopidogrel in medically managed ACS patients TOKYO and INDIANAPOLIS, June 23 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited, and Eli Lilly and Company said that the U.S. Food and Drug...
Worldwide COGENT-1 Study of CGT-2168 Expands to Europe; Focus on Reducing Gastrointestinal Side Effects of Antiplatelet Therapy MENLO PARK, Calif., June 16 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that the first patient has been enrolled in Europe in the company's pivotal Phase 3...
SAN DIEGO, June 16 /PRNewswire/ -- Patient enrollment into the GRAVITAS (Gauging Responsiveness With A VerifyNowR Assay-Impact On Thrombosis And Safety) trial has begun, officials from Accumetrics announced today. The GRAVITAS trial is designed to evaluate the use of the VerifyNow P2Y12 test to identify...
Research reveals that despite the perception of increased bleeding compared with Plavix, a large portion of physicians are likely to prescribe new competing drug prasugrel for ACS patients EAST HANOVER, N.J. -- Awareness and intent-to-prescribe levels are promising among physicians for the Phase III drug...
MIV Therapeutics, Inc. (OTCBB: MIVT)( www.mivtherapeutics.com ), a leading developer of next-generation coatingsand advanced drug delivery systems for cardiovascular stents and otherimplantable medical devices, was featured in Scientific American, a leadingonline science, health, and technology destination with more than 1,700,000visitors per month. The article by Larry Greenemeier, titled...
Upstate New Yorkers are spending a lot of money on prescription drugs, according to a new report from Excellus BlueCross BlueShield, the region's largest health in-surer. Of the more than 3,000 drugs prescribed in Upstate in 2007, 10 brand-name drugs accounted for about 20 percent of the total...
Considerable Opportunity Remains for an Antiplatelet Therapy that, Combined with Aspirin, Causes Less Bleeding than the Combination of Plavix/Iscover and Aspirin, According to a New Report from Decision Resources WALTHAM, Mass., May 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for...
A major trial has dashed the hope that the clot-preventing drug Plavix could help in the delicate balancing act needed to establish a blood vessel suitable for dialysis for kidney patients. Giving Plavix clopidogrel did reduce the risk that a blood clot would block the vessel created by combining a...
WORLD MARKETS Shares across the Continent fell, as renewed concern over the outlook for the financial sector and a record high oil price dragged on the broader market. Crude oil hovered above $126 a barrel, just shy of record highs. The French drug maker Sanofi-Aventis fell almost...
Review of Insurance Claims Tracked Ulcers and Bleeding Among 368,000 Patients Prescribed Clopidogrel TORONTO, May 6 /PRNewswire/ -- A review of medical claims from more than 70 managed care plans showed that 6.2 percent of patients prescribed the antiplatelet medicine clopidogrel submitted at least one insurance claim...
Simplicity at POC The DCA Vantage Analyzer, a point-of-care diabetes patient-management platform performs glycosylated hemoglobin (HbA1c), microalbumin/creatinine, and albumin-to-creatinine tests. The analyzer is critical for monitoring a patient's glycemic control and helps physicians encourage patient compliance by delivering actionable test results during a patient visit....
WASHINGTON AFP — A former senior vice president of Bristol-Myers Squibb Company BMS has been indicted for lying about a patent deal involving the blood-thinning drug Plavix, justice officials said Wednesday. Andrew Bodnar faces up to five years in prison and a fine of more than 250,000 dollars...
CHICAGO, March 29, 2008 AFP — A cocktail of new anti-blood clot drug Prasugrel and aspirin reduces the risk of stent-related clots more than the standard treatment, according to a clinical trial review presented Saturday. Prasugrel cut the risk of platelet formation around where a stent -- a...
CHICAGO, March 29 /PRNewswire/ -- - Reductions seen as soon as three days and out to 450 days in patients who received either bare metal or drug-eluting stents The investigational antiplatelet drug prasugrel plus aspirin produced a marked and...
Articles 2008-03-29
<< Previous
page 1 of 1
Next >>
Premier Vendor Content
Whitepapers, webcasts & resources from our Power Center Sponsors
Choose up to 5" more legroom with Economy Plus. Starting at $14.
Powerful, Dell is built to fit your business needs Customized systems, experts trained in small business, 24/7/365 support, and powerful, reliable technology. Dell, big results for small business.
Innovative USB Sleep'n Charge. Stylish Fusion™ finish. Ultra-portable. It's clear why the Satellite® U405 is a smart choice for you and your small business. Only from the laptop expert, Toshiba.
